news

CUPERTINO, Calif., Apr 8, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (Nasdaq:DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, April 24, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom […]

CUPERTINO, Calif., Apr 2, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has filed an Investigational New Drug application to investigate the delivery of cromolyn sodium for the treatment of asthma. This IND was filed as part of an ongoing program to develop a product for the treatment of asthma

CUPERTINO, Calif., Mar 27, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today a collaboration with Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services Center, Inc. to explore the feasibility of producing long acting soft gelatin based oral products, using the SABER(TM) technology as core formulations. The technology has the potential of greatly

CUPERTINO, Calif., Mar 18, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today the results from a pilot Phase III clinical study for its lead product in development, the CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the treatment of chronic pain. The CHRONOGESIC product is undergoing clinical investigation for the treatment of stable, opioid

CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2001. The Company’s net loss attributable to common stockholders for the three months ended December 31, 2001 was $10.1 million or 21 cents per share, compared to $4.9 million or 11 cents

CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it is sponsoring a symposium on novel drug delivery technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS) being held at the Hotel El Cid in Mazatlan, Sinaloa, Mexico, January 27th through February 1st, 2002. Dr. Randolph M. Johnson,

CUPERTINO, Calif., Jan 14, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (NASDAQ:DRRX) fourth quarter and year end 2001 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, January 30, 2002 at 4:30 p.m. EDT with Jim Brown, President and

CUPERTINO, Calif., Jan 4, 2002 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 20th Annual Healthcare Conference. The conference is taking place January 7-10th at The Westin St. Francis Hotel in San Francisco. James E. Brown, DVM, Chief Executive Officer will be presenting at the

CUPERTINO, Calif., Nov 16, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that ALZA Corporation has exercised its option to allow ALZA and Janssen Pharmaceutica Products, L.P., the right to begin negotiations for exclusive sales and marketing rights to DURECT’s lead pain management product, Chronogesic(TM) for the U.S. and Canada. Chronogesic(TM) is

CUPERTINO, Calif., Nov. 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Twelfth Annual Health Care Conference. The conference is taking place November 5-7 at The Plaza in New York City. Thomas A. Schreck, Chief Financial Officer will be presenting at the conference on Monday, November